BriaCell Therapeutics Corp
For the period ended Jul 31, 2024. Filed Oct 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Oct 29, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accountant Fees and Services
Audit Fees
The aggregate fees billed to us by MNP LLP, our independent registered public accounting firm, for the indicated services for each of the last two fiscal years were as follows:
| 2024 · 2023 | ||||
|---|---|---|---|---|
| Audit fees (1) | $210,778 | $153,000 | ||
| Audit-related fees (2) | $ | - | $113,000 | |
| Tax fees | $18,650 | $81,400 | ||
| All other fees | $14,530 | $ | - | |
| (1) | Audit fees consist of fees for professional services performed by MNP LLP for the audit and review of our quarterly financial statements. |
| (2) | Audit related fees consist of fees for preparation and filing of the carve-out financial statements related to the proxy statement filed. |
Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Auditors
Consistent with SEC policies and guidelines regarding audit independence, the Audit Committee is responsible for the pre-approval of all audit and permissible non-audit services provided by our independent registered public accounting firm on a case-by-case basis. Our Audit Committee has established a policy regarding approval of all audit and permissible non-audit services provided by our principal accountants. Our Audit Committee pre-approves these services by category and service. Our Audit Committee has pre-approved all of the services provided by our independent registered public accounting firm.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.